An original pharmaceutical product – Larifan (Lariphan) is developed at the Latvian Academy of Sciences and at present is produced at Larifāns Ltd (Larifan Ltd). Larifan is a patented, double-stranded RNA (dsRNA) of natural origin obtained from bacteriophage-infected E.coli cells.
Larifan possesses various biological activities like interferon – inducing immunomodulating, antiviral, antitumoral and antimutagenic properties. These activities are a result of the action of the induced endogenous interferon, but they also may be provoked directly by the dsRNA molecule. Currently, there are various product forms available, all of which contain the active ingredient dsRNS Larifan in varying concentrations.
National Export and Innovation Award | Larifan
2014. Larifan Ltd. with its antiviral and immunomodulating preparation “Larifan” received the Export and Innovation Award in the “Most Innovative Product” category.
Looking back at 2022 | Larifan
In 2022, Larifan actively participated in global pharmaceutical exhibitions, strengthened relations with cooperation partners and promoted the recognition of the company. Tashkent, Uzbekistan 12.04.2022 – 14.04.2022 Larifans participated in the Latvian national stand at the exhibition “Tashkent International Healthcare Exhibition – TIHE 2022”, from April…